{"id":"NCT00984815","sponsor":"Amgen","briefTitle":"Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment","officialTitle":"Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2009-09-25","resultsPosted":"2013-07-25","lastUpdate":"2024-12-18"},"enrollment":86,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis","Rheumatoid Arthritis","Chronic Low Back Pain","Chronic Regional Pain Syndrome","Chronic Soft Tissue Pain"],"interventions":[{"type":"DRUG","name":"HZT-501","otherNames":[]}],"arms":[{"label":"HZT-501","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events","timeFrame":"54 weeks","effectByArm":[{"arm":"HZT-501","deltaMin":76,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["25495134"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":86},"commonTop":["abdominal distension","dyspepsia","flatulence","sinusitis","diarrhoea"]}}